AI Article Synopsis

  • A 23-year-old male with lupus nephritis developed severe complications from the varicella-zoster virus, including meningoencephalomyelitis and visceral infection, after starting immunosuppressive therapy.
  • Despite treatment with intravenous acyclovir and additional supportive therapies, the patient experienced persistent symptoms and did not improve in muscle strength.
  • Financial constraints led the patient to discontinue therapy after one month, highlighting the challenges faced by immunocompromised patients dealing with serious infections.

Article Abstract

Rationale: Meningoencephalomyelitis and visceral dissemination infection are rare but life-threatening complications of either the primary infection or reactivation of varicella-zoster virus (VZV) in immunocompromised patients. To date, few studies have reported the co-existence of VZV meningoencephalomyelitis and the visceral dissemination of VZV infection.

Patient Concerns: A 23-year-old male was diagnosed with lupus nephritis class III and was being treated with oral prednisone and tacrolimus. The patient exhibited herpes zoster 21-day after the initiation of therapy and experienced unbearable abdominal pain and generalized seizures 11 days after the onset of a zoster rash. Magnetic resonance imaging showed progressive lesions in the cerebrum, brainstem, and cerebellum, as well as meningeal thickening and thoracic myelitis. Computed tomography showed pulmonary interstitial infiltration, partial intestinal dilatation, and effusion. Metagenomic next-generation sequencing revealed 198,269 and 152,222 VZV-specific reads in the cerebrospinal fluid and bronchoalveolar lavage fluid, respectively.

Diagnoses: Based on the clinical and genetic findings, this patient was finally diagnosed with VZV meningoencephalomyelitis and visceral disseminated VZV infection.

Interventions: The patient received intravenous acyclovir (0.5 g every 8 hours) combined with plasma exchange and intravenous immunoglobulin. Treatment against secondary bacterial and fungal infections, organ support therapy and rehabilitation training were given simultaneously.

Outcome: The patient's peripheral muscle strength did not improve and repeated metagenomic next-generation sequencing showed the persistence of VZV-specific reads in the cerebrospinal fluid. The patient finally abandoned therapy due to financial constraints at the 1-month follow-up.

Lessons: Patients with autoimmune diseases receiving immunosuppressive therapy should be warned about the possibility of developing serious neurological infections and visceral disseminated VZV infections as side effects. Early diagnosis and the early initiation of intravenous acyclovir therapy are important for such cases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082274PMC
http://dx.doi.org/10.1097/MD.0000000000033459DOI Listing

Publication Analysis

Top Keywords

varicella-zoster virus
12
visceral disseminated
12
meningoencephalomyelitis visceral
12
lupus nephritis
8
visceral dissemination
8
vzv meningoencephalomyelitis
8
metagenomic next-generation
8
next-generation sequencing
8
vzv-specific reads
8
reads cerebrospinal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!